Do you know any company at phase 2 trial taken over by big...

Do you know any company at phase 2 trial taken over by big pharmaceutical companies?

This does happen, I've counted over 100 since 2018 taken out either before or soon after a phase 2, through my own research - most of these for drugs in the more common & serious diseases (cancers, Alzheimer's, Schizo, Arthritis/Crohns/psoriasis/etc, cardio, metabolic).
But there are examples of some drugs in less common diseases, like our MSA, that have gone for big values;

• Forma Therapeutics $1.1bn USD mid ph 2/3 in Sickle cell disease
• Clementia Pharmaceuticals $1.04bn USD after ph 2 in Fibrodysplasia Ossificans Progressiva
• Jnana Therapeutics $800M USD mid ph 1 in PKU

If we do get Accelerated approval then it could jump us up IMO:

• Reata Pharmaceuticals $7.3bn, FDA accelerated approval off ph 2 in Friedrich's ataxia
• Global Blood Therapeutics $5.4bn, FDA AA off ph 3 in Sickle cell disease
• CymaBay $4.3bn, pre-FDA AA of ph 3 in Primary Biliary Cholangitis

Even some good good examples of buy out mid ph 3, which Alterity may be in that position in coming year:

• Morphosys €2.7bn in Myelofibrosis
• Longboard Pharmaceuticals $2.6bn USD in Epileptic Encephalopathies
• Ra Pharma $2.1bn USD in Myasthenia gravis

These are some of the higher prices deals, so there are some lower price deals I didn't mention, but I feel our team with strong negotiating experience and great data can push for these. If we have compelling evidence in other diseases then that would help a lot too. Not saying this will happen, Stamler and co may well want to partner and develop many indications separately, but just pointing out that it can and does happen. Cheers.